Clinical Trial Update: Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of cipatinib for HER2-positive or uncertain advanced breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Cipatinib (cipatinib)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED